Cargando…

Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis

OBJECTIVE: Nonadherence to disease‐modifying antirheumatic drugs (DMARDS) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) results in increased disease activity and symptoms and poorer quality of life. We aimed to describe patients’ attitudes and experiences of DMARDs in RA and SpA to inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Ayano, Tymms, Kathleen, Tunnicliffe, David J., Sumpton, Daniel, Perera, Chandima, Fallon, Kieran, Craig, Jonathan C., Abhayaratna, Walter, Tong, Allison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901029/
https://www.ncbi.nlm.nih.gov/pubmed/28732151
http://dx.doi.org/10.1002/acr.23329
_version_ 1783314529024737280
author Kelly, Ayano
Tymms, Kathleen
Tunnicliffe, David J.
Sumpton, Daniel
Perera, Chandima
Fallon, Kieran
Craig, Jonathan C.
Abhayaratna, Walter
Tong, Allison
author_facet Kelly, Ayano
Tymms, Kathleen
Tunnicliffe, David J.
Sumpton, Daniel
Perera, Chandima
Fallon, Kieran
Craig, Jonathan C.
Abhayaratna, Walter
Tong, Allison
author_sort Kelly, Ayano
collection PubMed
description OBJECTIVE: Nonadherence to disease‐modifying antirheumatic drugs (DMARDS) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) results in increased disease activity and symptoms and poorer quality of life. We aimed to describe patients’ attitudes and experiences of DMARDs in RA and SpA to inform strategies to improve medication adherence. METHODS: Databases (MEDLINE, Embase, PsycINFO, and CINAHL) were searched to January 2016. Thematic synthesis was used to analyze the findings. RESULTS: From 56 studies involving 1,383 adult patients (RA [n = 1,149], SpA [n = 191], not specified [n = 43]), we identified 6 themes (with subthemes): intensifying disease identity (severity of sudden pharmacotherapy, signifying deteriorating health, daunting lifelong therapy), distressing uncertainties and consequences (poisoning the body, doubting efficacy, conflicting and confusing advice, prognostic uncertainty with changing treatment regimens), powerful social influences (swayed by others’ experiences, partnering with physicians, maintaining roles, confidence in comprehensive and ongoing care, valuing peer support), privilege and right of access to biologic agents (expensive medications must be better, right to receive a biologic agent, fearing dispossession), maintaining control (complete ownership of decision, taking extreme risks, minimizing lifestyle intrusion), and negotiating treatment expectations (miraculous recovery, mediocre benefit, reaching the end of the line). CONCLUSION: Patients perceive DMARDs as strong medications with alarming side effects that intensify their disease identity. Trust and confidence in medical care, positive experiences with DMARDS among other patients, and an expectation that medications will help maintain participation in life can motivate patients to use DMARDs. Creating a supportive environment for patients to voice their concerns may improve treatment satisfaction, adherence, and health outcomes.
format Online
Article
Text
id pubmed-5901029
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59010292018-04-24 Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis Kelly, Ayano Tymms, Kathleen Tunnicliffe, David J. Sumpton, Daniel Perera, Chandima Fallon, Kieran Craig, Jonathan C. Abhayaratna, Walter Tong, Allison Arthritis Care Res (Hoboken) Rheumatoid Arthritis OBJECTIVE: Nonadherence to disease‐modifying antirheumatic drugs (DMARDS) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) results in increased disease activity and symptoms and poorer quality of life. We aimed to describe patients’ attitudes and experiences of DMARDs in RA and SpA to inform strategies to improve medication adherence. METHODS: Databases (MEDLINE, Embase, PsycINFO, and CINAHL) were searched to January 2016. Thematic synthesis was used to analyze the findings. RESULTS: From 56 studies involving 1,383 adult patients (RA [n = 1,149], SpA [n = 191], not specified [n = 43]), we identified 6 themes (with subthemes): intensifying disease identity (severity of sudden pharmacotherapy, signifying deteriorating health, daunting lifelong therapy), distressing uncertainties and consequences (poisoning the body, doubting efficacy, conflicting and confusing advice, prognostic uncertainty with changing treatment regimens), powerful social influences (swayed by others’ experiences, partnering with physicians, maintaining roles, confidence in comprehensive and ongoing care, valuing peer support), privilege and right of access to biologic agents (expensive medications must be better, right to receive a biologic agent, fearing dispossession), maintaining control (complete ownership of decision, taking extreme risks, minimizing lifestyle intrusion), and negotiating treatment expectations (miraculous recovery, mediocre benefit, reaching the end of the line). CONCLUSION: Patients perceive DMARDs as strong medications with alarming side effects that intensify their disease identity. Trust and confidence in medical care, positive experiences with DMARDS among other patients, and an expectation that medications will help maintain participation in life can motivate patients to use DMARDs. Creating a supportive environment for patients to voice their concerns may improve treatment satisfaction, adherence, and health outcomes. John Wiley and Sons Inc. 2018-03-24 2018-04 /pmc/articles/PMC5901029/ /pubmed/28732151 http://dx.doi.org/10.1002/acr.23329 Text en © 2017, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Rheumatoid Arthritis
Kelly, Ayano
Tymms, Kathleen
Tunnicliffe, David J.
Sumpton, Daniel
Perera, Chandima
Fallon, Kieran
Craig, Jonathan C.
Abhayaratna, Walter
Tong, Allison
Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
title Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
title_full Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
title_fullStr Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
title_full_unstemmed Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
title_short Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
title_sort patients’ attitudes and experiences of disease‐modifying antirheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901029/
https://www.ncbi.nlm.nih.gov/pubmed/28732151
http://dx.doi.org/10.1002/acr.23329
work_keys_str_mv AT kellyayano patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT tymmskathleen patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT tunnicliffedavidj patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT sumptondaniel patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT pererachandima patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT fallonkieran patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT craigjonathanc patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT abhayaratnawalter patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis
AT tongallison patientsattitudesandexperiencesofdiseasemodifyingantirheumaticdrugsinrheumatoidarthritisandspondyloarthritisaqualitativesynthesis